|
|||||
|
|
Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy |
|
| Authors: | David Beauvais Oriane Karleskind Severine Loridant Remy Nyga Marie Lamiaux Anne-Sophie Moreau Franck Morschhauser Suman Mitra Ibrahim Yakoub-Agha Boualem Sendid |
| Affiliation: | 1. Univ. Lille, CHU Lille, Department of Haematology, F-59000, Lille, France;2. CHU Lille, Institut de Pathologie, Centre de Biologie Pathologie Génétique, F-59000, Lille, France;3. Univ. Lille, Inserm U1285, CNRS UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France;4. CHU Lille, Service de Parasitologie Mycologie, F-59037 Lille, France;5. CHU Lille, Critical Care Centre, F-59000, Lille, France;6. University of Lille, Inserm, UMR-S 1172, F-59000, Lille, France;7. University of Lille, CHU Lille, Inserm, Infinite, U1286, F-59000 Lille, France |
| Abstract: | We report a septicemia and disseminated candidiasis due to delayed gastrointestinal mucosae repair in a patient treated with tocilizumab after anti-CD19 CAR T-cell therapy. Tocilizumab could have inhibited intestinal tissue repair and furthered bacteria translocation leading to the invasion of intestinal mucosa by yeasts as IL-6 is known to be involved in mucosal wound healing. |
| Keywords: | CAR T-cell Il-6 tocilizumab |
| 本文献已被 ScienceDirect 等数据库收录！ | |